A practical reference on bioavailability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-23. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
As a prototypical transaminase, AST relies on PLP (vitamin B6) as a cofactor to transfer the amino group from aspartate or glutamate to the corresponding ketoacid. In the process, the cofactor shuttles between PLP and the pyridoxamine phosphate (PMP) form. The amino group transfer catalyzed by this enzyme is crucial in both amino acid degradation and biosynthesis. In amino acid degradation, following the conversion of α-ketoglutarate to glutamate, glutamate subsequently undergoes oxidative deamination to form ammonium ions, which are excreted as urea. In the reverse reaction, aspartate may be synthesized from oxaloacetate, which is a key intermediate in the citric acid cycle. Two isoenzymes are present in a wide variety of eukaryotes. In humans:
One more very convincing experiment from Dubna was published in 1966 (though it was submitted in 1965), again using the same two reactions, which concluded that 254No indeed had a half-life much longer than the 3 seconds claimed by Berkeley. Later work in 1967 at Berkeley and 1971 at the Oak Ridge National Laboratory fully confirmed the discovery of element 102 and clarified earlier observations. In December 1966, the Berkeley group repeated the Dubna experiments and fully confirmed them, and used this data to finally assign correctly the isotopes they had previously synthesized but could not yet identify at the time. Thus they claimed to have discovered nobelium in 1958 to 1961.
The Meeting of Teano between Garibaldi and King Victor Emmanuel II of Savoy took place on 26 October 1860, where he annexed Mezzogiorno. On 19 August 1860, Calabria was invaded from Sicily by Giuseppe Garibaldi and his Redshirts as part of the Expedition of the Thousand. Through King Francesco II of Naples had dispatched 16,000 soldiers to stop the Redshirts, who numbered about 3,500, after a token battle at Reggio Calabria won by the Redshirts, all resistance ceased and Garibaldi was welcomed as a liberator from the oppressive rule of the Bourbons wherever he went in Calabria. Calabria together with the rest of the Kingdom of Naples was incorporated in 1861 into the Kingdom of Italy. Garibaldi planned to complete the Risorgimento by invading Rome, still ruled by the pope protected by a French garrison, and began with semi-official encouragement to raise an army. Subsequently, King Victor Emmanuel II decided the possibility of war with France was too dangerous, and on 29 August 1862 Garibaldi's base in the Calabrian town of Aspromonte was attacked by the Regio Esercito. The Battle of Aspromonte ended with the Redshirts defeated with several being executed after surrendering while Garibaldi was badly wounded. With the plebiscite of 21 October 1860, Calabria and the other southern provinces became part of the Kingdom of Sardinia: consequently, elections were called to allow the newly annexed territories to select representation in Parliament. The election was held on 27 January 1861, and the new Parliament was inaugurated in Turin on February 18.
Sources: en.wikipedia.org
=== EC 1.6.99 With unknown physiological acceptors === EC 1.6.99.1: NADPH dehydrogenase EC 1.6.99.2: Now EC 1.6.5.2, NAD(P)H dehydrogenase (quinone EC 1.6.99.3: The activity is covered by EC 7.1.1.2, NADH:ubiquinone reductase (H+-translocating) EC 1.6.99.4: Now EC 1.18.1.2, ferredoxin—NADP+ reductase EC 1.6.99.5: Now EC 1.6.5.11, NADH dehydrogenase (quinone) EC 1.6.99.6: Now EC 1.6.5.10, NADPH dehydrogenase (quinone) EC 1.6.99.7: Now EC 1.5.1.34, 6,7-dihydropteridine reductase EC 1.6.99.8: Deleted EC 1.6.99.9: Now EC 1.16.1.4, cob(II)alamin reductase EC 1.6.99.10: included in EC 1.5.1.34, 6,7-dihydropteridine reductase EC 1.6.99.11: Deleted EC 1.6.99.12: Now EC 1.16.1.6, cyanocobalamin reductase (cyanide-eliminating) EC 1.6.99.13: Now EC 1.16.1.7, ferric-chelate reductase
== Structure == The chondrocyte in cartilage matrix has rounded or polygonal structure. The exception occurs at tissue boundaries, for example the articular surfaces of joints, in which chondrocytes may be flattened or discoid. Intra-cellular features are characteristic of a synthetically active cell. The cell density of full-thickness, human, adult, femoral condyle cartilage is maintained at 14.5 (±3.0) × 103 cells/ mm2 from age 20 to 30 years. Although chondrocyte senescence occurs with aging, mitotic figures are not seen in normal adult articular cartilage. The structure, density, and synthetic activity of an adult chondrocyte are various according to its position. Flattened cells are oriented parallel to the surface, along with the collagen fibers, in the superficial zone, the region of highest cell density. In the middle zone, chondrocytes are larger and more rounded and display a random distribution, in which the collagen fibers also are more randomly arranged. In the deeper zones, chondrocytes form columns that are oriented perpendicular to the cartilage surface, along with the collagen fibers. Different behaviors may be exhibited by chondrocytes depending on their position within the different layers. In primary chondrocyte cultures, these zonal differences in synthetic properties may persist. The primary cilia are significant for spatial orientation of cells in developing growth plate and are sensory organelles in chondrocytes. Primary cilia work as centers for wingless type (Wnt) and hedgehog signaling and contain mechanosensitive receptors.
=== Tour === Clipse announced a United States concert tour in promotion of the album on June 9, consisting of twenty-five planned shows from August 3 to September 10. Atlanta hip-hop duo EarthGang is the planned supporting act. Four dates in Europe were added on July 14, extending the tour's window to November 10.
NASA Radioisotope Power Systems website – RTG page NASA JPL briefing, Expanding Frontiers with Radioisotope Power Systems – gives RTG information and a link to a longer presentation SpaceViews: The Cassini RTG Debate Stirling Radioisotope Generator DOE contributions – good links Idaho National Laboratory – Producer of RTGs Idaho National Laboratory MMRTG page with photo-based "virtual tour"
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.